Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients (Q45224264)

11 December 2017

Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients (English)

1 reference

11 December 2017

1 reference

1 reference

An Wang

1

1 reference

11 December 2017

Bang-Ning Yu

2

1 reference

11 December 2017

Chen-Hui Luo

3

1 reference

11 December 2017

Zhi-Rong Tan

4

1 reference

11 December 2017

Gan Zhou

5

1 reference

11 December 2017

Lian-Sheng Wang

6

1 reference

11 December 2017

Wei Zhang

7

1 reference

11 December 2017

Zhi Li

8

1 reference

11 December 2017

Jie Liu

9

1 reference

11 December 2017

Hong-Hao Zhou

10

1 reference

11 December 2017

14 January 2005

1 reference

European Journal of Clinical Pharmacology

11 December 2017

1 reference

11 December 2017

60

1 reference

11 December 2017

12

1 reference

11 December 2017

843-848

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-004-0848-7

11 December 2017

0 references

cites work

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

1 reference

12 December 2020

Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction

1 reference

12 December 2020

The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction

1 reference

12 December 2020

Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo

1 reference

12 December 2020

Clinical pharmacokinetics and practical applications of simvastatin

1 reference

12 December 2020

Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6beta-hydroxycortisol in routine practice. For CYP 3A4 activity evaluation in basal conditions and after grapefruit juice

1 reference

12 December 2020

Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4

1 reference

12 December 2020

In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s

1 reference

12 December 2020

Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

1 reference

12 December 2020

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

1 reference

12 December 2020

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

1 reference

12 December 2020

The efficacy of simvastatin is not influenced by CYP2D6 polymorphism.

1 reference

12 December 2020

Cytochrome P-450 3A4: regulation and role in drug metabolism

1 reference

12 December 2020

Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?

1 reference

12 December 2020

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

1 reference

12 December 2020

Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4

1 reference

12 December 2020

Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.

1 reference

12 December 2020

Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug

1 reference

12 December 2020

CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.

1 reference

12 December 2020

RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4

1 reference

12 December 2020

Common allelic variants of cytochrome P4503A4 and their prevalence in different populations

1 reference

12 December 2020

Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4

1 reference

12 December 2020

Novel mutations of CYP3A4 in Chinese

1 reference

12 December 2020

Identification and functional characterization of eight CYP3A4 protein variants

1 reference

12 December 2020

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

1 reference

12 December 2020

Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis.

1 reference

12 December 2020

Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region

1 reference

12 December 2020

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

1 reference

12 December 2020

Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general.

1 reference

12 December 2020

Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans

1 reference

12 December 2020

Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone.

1 reference

12 December 2020

10.1007/S00228-004-0848-7

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

0 references

1 reference